Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.09 and traded as high as $3.86. Achieve Life Sciences shares last traded at $3.81, with a volume of 235,411 shares.
Achieve Life Sciences Price Performance
The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.85. The stock has a market cap of $132.15 million, a price-to-earnings ratio of -2.84 and a beta of 1.63. The company's 50-day moving average is $2.97 and its 200-day moving average is $3.09.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). Equities research analysts expect that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its holdings in shares of Achieve Life Sciences by 185.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 4,905 shares in the last quarter. Sigma Planning Corp acquired a new stake in shares of Achieve Life Sciences during the fourth quarter worth approximately $37,000. AQR Capital Management LLC acquired a new stake in shares of Achieve Life Sciences during the first quarter worth approximately $32,000. ADAR1 Capital Management LLC increased its holdings in shares of Achieve Life Sciences by 14,375.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 13,173 shares of the biopharmaceutical company's stock worth $46,000 after buying an additional 13,082 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Achieve Life Sciences during the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 33.52% of the company's stock.
Achieve Life Sciences Company Profile
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
